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Introduction {#bjs11092-sec-0005}
============

Low anterior resection with total mesorectal excision is a common surgical option for patients with potentially curable rectal cancer. Anastomotic leakage is a feared complication after anterior resection as it is associated with a 6--22 per cent increase in postoperative mortality and may result in worse oncological outcomes[1](#bjs11092-bib-0001){ref-type="ref"}, [2](#bjs11092-bib-0002){ref-type="ref"}. A temporary ileostomy created at the time of the rectal resection may ameliorate the clinical consequences of a potential anastomotic leak[3](#bjs11092-bib-0003){ref-type="ref"}, [4](#bjs11092-bib-0004){ref-type="ref"}, [5](#bjs11092-bib-0005){ref-type="ref"}, [6](#bjs11092-bib-0006){ref-type="ref"}. Typically, patients have a stoma for approximately 5--6 months[7](#bjs11092-bib-0007){ref-type="ref"}, [8](#bjs11092-bib-0008){ref-type="ref"}, [9](#bjs11092-bib-0009){ref-type="ref"}, which may have a negative impact on their quality of life[10](#bjs11092-bib-0010){ref-type="ref"}, [11](#bjs11092-bib-0011){ref-type="ref"}, renal function[12](#bjs11092-bib-0012){ref-type="ref"}, [13](#bjs11092-bib-0013){ref-type="ref"}, [14](#bjs11092-bib-0014){ref-type="ref"}, [15](#bjs11092-bib-0015){ref-type="ref"} and completion of chemotherapy[16](#bjs11092-bib-0016){ref-type="ref"}. Early closure of an ileostomy, less than 2 weeks after primary resection, has been shown to be safe in selected patients in randomized trials[17](#bjs11092-bib-0017){ref-type="ref"}, [18](#bjs11092-bib-0018){ref-type="ref"}.

Low anterior resection syndrome (LARS) describes bowel dysfunction after surgical resection of rectal cancer. Identified risk factors for LARS are radiotherapy and low anastomosis[19](#bjs11092-bib-0019){ref-type="ref"}, [20](#bjs11092-bib-0020){ref-type="ref"}, [21](#bjs11092-bib-0021){ref-type="ref"}, [22](#bjs11092-bib-0022){ref-type="ref"}, [23](#bjs11092-bib-0023){ref-type="ref"}. The underlying mechanisms are likely to be multifactorial, and include neural damage, fibrosis and altered colonic motility[24](#bjs11092-bib-0024){ref-type="ref"}. Use of a diverting stoma has been associated with postrectal resection bowel dysfunction in non‐controlled studies[23](#bjs11092-bib-0023){ref-type="ref"}, [25](#bjs11092-bib-0025){ref-type="ref"}, [26](#bjs11092-bib-0026){ref-type="ref"}, [27](#bjs11092-bib-0027){ref-type="ref"}. Theoretically, this association may be due to alterations in colonic nutrition leading to inflammation, changes in the bacterial flora, and/or atrophy of motility or sensory elements[28](#bjs11092-bib-0028){ref-type="ref"}. Therefore, the duration of a diverting ileostomy may influence the occurrence of LARS.

The aim of this study was to conduct a secondary analysis of the multicentre EASY (Early Closure of Temporary Ileostomy) RCT (NCT01287637), using specifically designed instruments to assess whether patients who undergo early closure of the ileostomy after anterior resection for rectal cancer have a reduced risk of developing LARS compared with those who undergo late closure. A secondary aim was to assess whether the two validated instruments specifically designed to measure postoperative bowel function, the LARS score and the Memorial Sloan Kettering Cancer Center (MSKCC) Bowel Function Instrument (BFI), were measuring the same underlying construct.

Methods {#bjs11092-sec-0006}
=======

The EASY trial was a multicentre RCT conducted in eight Danish and Swedish surgical departments within the Scandinavian Surgical Outcomes Research Group framework (<http://www.ssorg.net>). The trial protocol[29](#bjs11092-bib-0029){ref-type="ref"} is available at [http://bmjopen.bmj.com/content/early/2011/07/29/bmjopen‐2011‐000162.short](http://bmjopen.bmj.com/content/early/2011/07/29/bmjopen-2011-000162.short). Adults who had undergone a low anterior resection with temporary ileostomy formation for the treatment of rectal cancer were eligible. Participants were enrolled after the index surgery (total mesorectal excision and formation of temporary ileostomy) between February 2011 and November 2014. Potential participants were assessed clinically on day 1--4 after index surgery to ensure that there were no signs of postoperative complications, such as infection or anastomotic leakage. The exclusion criteria were: diabetes, ongoing steroid treatment, signs of postoperative complication(s), and inability to understand Danish or Swedish. Before randomization, anastomotic integrity was ensured between days 6 and 8 after the index surgery, by CT with contrast and/or direct visualization using rectoscopy.

Randomization was performed in computer‐generated blocks of six, using opaque, sealed envelopes with a 1 : 1 ratio. Blinding was not possible. Participants randomized to the intervention (early closure) had the ileostomy closed within 8--13 days after index surgery. Participants allocated to the control group (late closure) had the ileostomy closed at a minimum of 12 weeks after the index surgery. The primary endpoint of the study was the rate of complications. Secondary endpoints included health‐related quality of life up to 12 months after rectal resection. These results have been published previously[17](#bjs11092-bib-0017){ref-type="ref"}, [30](#bjs11092-bib-0030){ref-type="ref"}.

An invitation to participate in further follow‐up regarding functional outcome was sent to all surviving participants between August and October 2017. All participants received the study questionnaire by post. Participants received up to two follow‐up telephone calls. Functional follow‐up comprised completion of two questionnaires, the LARS score and the BFI. The LARS score is derived from responses to five questions, each with associated response categories based on the frequency of symptom occurrence or number of bowel motions (*Appendix*  *S1*, supporting information)[31](#bjs11092-bib-0031){ref-type="ref"}. Each response is weighted based on the impact on quality of life. A LARS score of 0--20 represents no LARS, 21--29 minor LARS, and 30--42 major LARS. The BFI consists of 18 questions that are divided into subscales as suggested by the authors: dietary, soiling/urgency and frequency (*Appendix*  *S2*, supporting information)[32](#bjs11092-bib-0032){ref-type="ref"}. The BFI gives an overall score between 0 and 100, with a higher score representing better function. The overall BFI score and the score for each subscale were calculated. Numerical responses to question 1 (frequency of bowel motions per 24 h) were divided into quintiles, with the fifth quintile representing the lowest frequency and given a response of 5 on the ordinal scale, as advised by the authors of the BFI[32](#bjs11092-bib-0032){ref-type="ref"}. For questions 4, 5, 7, 11 and 12, a response of 'always' represented the best possible function, so was given the maximum score of 5. For all other questions, a response of 'always' represented the worst function, so was given the minimum score of 1. If participants returned questionnaires with multiple responses to a single question, the response that indicated the most severe outcome was used in the analysis. Mean imputation was used to allow calculation of subscale scores that contained missing responses if at least 50 per cent of questions in the subscale were answered. If more than 50 per cent of items in a subscale were missing, the subscale was recorded as missing. There were no missing subscales, but mean imputation was used to calculate 12 subscale scores.

Statistical analysis {#bjs11092-sec-0007}
--------------------

An intention‐to‐treat analysis was used. Comparison between treatment groups was undertaken using χ^2^ test or Fisher\'s exact test for categorical variables, and Mann--Whitney *U* test for continuous variables. Tests of significance were two‐sided and the level of significance was 0·05. LARS was analysed as a dichotomized variable (no/minor and major) using a generalized linear model with binomial distribution[33](#bjs11092-bib-0033){ref-type="ref"}. In an adjusted analysis, tumour height and use of radiotherapy were included as co‐variables. Results are presented as a risk ratio with 95 per cent confidence intervals. No corrections for multiplicity were made. The correlation between responses from the BFI and LARS scores was assessed using the Spearman rank order correlation coefficient. SPSS^®^ Statistics for Macintosh^®^ version 24.0 (IBM, Armonk, New York, USA) and GraphPad Prism^®^ version 7 for Mac OS X (GraphPad Software, La Jolla, California, USA) were used for statistical analysis.

Results {#bjs11092-sec-0008}
=======

The EASY trial enrolled 112 participants. There were 100 participants alive at the time of functional follow‐up. Median follow‐up was 50 (range 34--77) months after index surgery and 49 (range 24--74) months after stoma closure. One of 42 participants in the early closure group had a permanent stoma, compared with six of 40 in the late closure group (*P* = 0·054); two of the latter patients had the stoma because of persisting severe bowel dysfunction (*Table*  [1](#bjs11092-tbl-0001){ref-type="table"}). Of the remaining 93 patients, 82 (88 per cent) responded to the functional questionnaires (*Fig*. [1](#bjs11092-fig-0001){ref-type="fig"}).

###### 

Reasons for formation of a permanent stoma in patients lost to follow‐up

  Reason for permanent stoma                                                                                                                         No. of patients
  ------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  **Early closure group**                                                                                                                                   1
  Anastomotic leak and associated necrotizing fasciitis\>12 months after stoma closure                                                                      1
  **Late closure group**                                                                                                                                    6
  Bowel dysfunction -- patient preference for stoma\>12 months after stoma closure                                                                          2
  Stenosis \<12 months after stoma closure                                                                                                                  1
  Anastomotic stricture dilated and perforated withresulting sepsis and cardiopulmonary arrest(grade IVa[\*](#bjs11092-note-0002){ref-type="fn"})           1
  Anastomotic leak 9 months after stoma closure                                                                                                             1
  Unknown                                                                                                                                                   1

According to Clavien--Dindo classification[34](#bjs11092-bib-0034){ref-type="ref"}.

![CONSORT flow diagram for EASY trial[17](#bjs11092-bib-0017){ref-type="ref"} \*Paralytic ileus (24 patients), Hartmann\'s procedure with intersphincteric dissection (16), delayed postoperative recovery (15), perioperative complications (7), other infection (5), reoperation (7), high stoma output (5), pulmonary embolism (1), ulcerative colitis (1), extensive cancer disease (3), cardiovascular disease (2), language difficulties (5), diabetes (28), permanent or no stoma (29), steroid treatment (3), other (8). †Centre 6 (2 patients), centre 7 (3) and centre 8 (3). ‡Allocated to early closure, but not possible to carry out operation within 8--13 days (1 patient), early stoma closure outside study (2), patient randomized, but no further information available (1). LARS, low anterior resection syndrome; MSKCC, Memorial Sloan Kettering Cancer Center.](BJS-106-645-g001){#bjs11092-fig-0001}

Participant and treatment characteristics are summarized in *Table*  [2](#bjs11092-tbl-0002){ref-type="table"}. There were more women in the early closure group (22 of 42 *versus* 12 of 40; *P* = 0·047), but there were no other differences in participant or treatment characteristics between the groups. Median follow‐up after restoration of bowel continuity in the early and late closure groups was 52 and 44 months respectively. There were no differences in any characteristics between participants who responded to the questionnaires and those who did not complete functional follow‐up.

###### 

Participant and treatment characteristics

                                                                                 Early closure (*n* = 42)              Late closure (*n* = 40)
  ----------------------------------------------------------------------------- -------------------------- ------------------------------------------------
  **Age (years)** [\*](#bjs11092-note-0003){ref-type="fn"}                                                 
  At index surgery                                                                     67 (53--71)                           68 (63--73)
  At follow‐up (years)[\*](#bjs11092-note-0003){ref-type="fn"}                         71 (58--76)                           72 (67--77)
  **Sex ratio (F : M)**                                                                  22 : 20            12 : 28[¶](#bjs11092-note-0007){ref-type="fn"}
  **BMI (kg/m^2^)** [\*](#bjs11092-note-0003){ref-type="fn"}                           24 (23--27)                           24 (22--26)
  **Co‐morbidity** [†](#bjs11092-note-0004){ref-type="fn"}                                                 
  Ischaemic heart disease                                                                   5                                     6
  Hypertension                                                                              14                                    7
  COPD                                                                                      2                                     1
  Renal disease                                                                             0                                     0
  Other[‡](#bjs11092-note-0005){ref-type="fn"}                                              5                                     1
  **Smoker**                                                                                4                                     2
  **Clinical stage (UICC)** [§](#bjs11092-note-0006){ref-type="fn"}                                        
  I                                                                                         11                                    12
  II                                                                                        18                                    10
  III                                                                                       11                                    13
  IV                                                                                        1                                     1
  **Tumour height (cm from anal verge)**                                                                   
  5--9                                                                                      23                                    16
  10--15                                                                                    18                                    24
  ≥ 15                                                                                      1                                     0
  **Radiotherapy**                                                                          11                                    10
  Short course                                                                              9                                     7
  Long course                                                                               2                                     3
  **Adjuvant chemotherapy**                                                                 13                                    18
  **Duration of ileostomy (days)** [\*](#bjs11092-note-0003){ref-type="fn"}            11 (10--14)                          150 (100--251)
  **Duration of follow‐up (months)** [\*](#bjs11092-note-0003){ref-type="fn"}                              
  From index surgery                                                                   52 (44--59)                           49 (43--58)
  From stoma closure                                                                   52 (44--59)                           44 (35--53)

Values are median (i.q.r.).

Data missing for two patients in the late closure group.

In early closure group: asthma (1), Waldenstrom macroglobulinaemia/non‐Hodgkin\'s lymphoma (1), osteoporosis (1), Sjögren\'s syndrome (1), thyrotoxicosis (1); in late closure group: hypercholesterolaemia (1).

Three patients with late closure had clinical stage T0 N0 M0 disease; data on clinical stage missing for one patient in each group. COPD, chronic obstructive pulmonary disease.

*P* = 0·047 (2‐sided Fisher\'s exact test).

Low anterior resection syndrome score {#bjs11092-sec-0009}
-------------------------------------

Overall, 54 patients reported major LARS (66 per cent; 25 in early group and 29 in late group), 12 reported minor LARS (15 per cent; 7 and 5 participants respectively) and 16 reported no LARS (20 per cent; 10 and 6 participants respectively). The median LARS scores for the early and late closure groups were 31 (i.q.r. 22--36) and 34 (28--39) respectively (*Fig*. [2](#bjs11092-fig-0002){ref-type="fig"}). The prevalence of LARS (major or minor) was 32 of 42 and 34 of 40 in the early and late closure groups respectively (risk ratio 0·89, 95 per cent c.i. 0·72 to 1·11; *P* = 0·291). The results were similar after adjusting for tumour height and use of radiotherapy (risk ratio 0·89, 0·72 to 1·11; *P* = 0·314).

![Distribution of lower anterior resection syndrome scores for participants with early and late ileostomy closure Median scores (bold line), interquartile range (box) and 5--95th percentile (error bars) are shown. Symbols represent outliers. Boundaries between the lower anterior resection syndrome (LARS) categories are denoted by dashed lines.](BJS-106-645-g002){#bjs11092-fig-0002}

Higher rates of incontinence to faeces (21 of 42 *versus* 28 of 40; *P* = 0·076) and flatus (36 of 42 *versus* 36 of 40; *P* = 0·738), increased stool frequency (14 of 42 *versus* 15 of 40; *P* = 0·818), clustering (36 of 42 *versus* 37 of 40; *P* = 0·483) and urgency (33 of 42 *versus* 33 of 40; *P* = 0·783) were found in the late closure group, but were not statistically significant.

Memorial Sloan Ketting Cancer Center Bowel Function Instrument {#bjs11092-sec-0010}
--------------------------------------------------------------

There were no significant differences between early and late closure with regard to median overall BFI scores (71 (i.q.r. 59--75) and 63 (60--70) respectively; *P* = 0·207) or the frequency (22 (21--25) *versus* 22 (20--24); *P* = 0·437) and dietary (16 (13--18) *versus* 16 (12--18); *P* = 0·939) subscales (*Fig*. [3](#bjs11092-fig-0003){ref-type="fig"}). However, patients undergoing late closure had worse scores on the urgency/soiling subscale than those in the early closure group (14 (6--18) *versus* 17 (9--20); *P* = 0·017).

![Distribution of Memorial Sloan Kettering Cancer Center Bowel Function Instrument scores for participants with early and late ileostomy closure Median scores (bold line), interquartile range (box) and 5--95th percentile (error bars) are shown. Symbols represent outliers. Higher scores represent better function.](BJS-106-645-g003){#bjs11092-fig-0003}

A strong negative correlation was noted between the two scoring systems specifically designed to measure LARS (ρ = -- 0·72, *P \<* 0·001). The coefficient of variation was 70 per cent for the LARS score compared with 16 per cent for the BFI.

Discussion {#bjs11092-sec-0011}
==========

The results of this study indicate that a substantial proportion of participants have severe bowel dysfunction many months after ileostomy reversal. Participants in the late closure group had worse scores on the soiling/urgency subscale of the BFI. Despite higher rates of bowel dysfunction, including more permanent stomas in the late closure group, there was no statistically significant difference in LARS between the groups.

This is the first assessment of whether patients who undergo early closure of ileostomy after anterior resection for rectal cancer have less risk of developing LARS. A single retrospective analysis[23](#bjs11092-bib-0023){ref-type="ref"} investigated the association between timing of ileostomy closure and LARS, and found no association. However, all participants in that study had an ileostomy for at least 3 months.

The overall prevalence of major LARS in this study (66 per cent) is higher than might be expected from the literature. Only one‐quarter of participants received radiotherapy, all tumours were above 5 cm and half were more than 10 cm above the anal verge. It is possible that this study offers a more accurate representation of the population prevalence as there was a high response rate (88 per cent) and so minimal selection bias. The high prevalence of LARS in this study may reflect the evaluation of a population at inherently greater risk of developing LARS, that is patients requiring an ileostomy. Several non‐controlled studies[20](#bjs11092-bib-0020){ref-type="ref"}, [23](#bjs11092-bib-0023){ref-type="ref"}, [26](#bjs11092-bib-0026){ref-type="ref"} have shown an association between use of a temporary ileostomy and LARS. However, this association could be the result of confounding factors as patients with a distal tumour who undergo radiotherapy are at greater risk of developing LARS, but are also at higher risk of anastomotic leakage and more likely to have an ileostomy[23](#bjs11092-bib-0023){ref-type="ref"}, [26](#bjs11092-bib-0026){ref-type="ref"}. In the present study, similar results were obtained in unadjusted analysis and after adjusting for tumour height and use of radiotherapy.

The BFI scores for the late closure group are consistent with those in previous studies[32](#bjs11092-bib-0032){ref-type="ref"}, [35](#bjs11092-bib-0035){ref-type="ref"}, [36](#bjs11092-bib-0036){ref-type="ref"}. An interesting finding of the present study is that patients who had late ileostomy closure experienced greater problems with soiling, according to the BFI subscale. This subscale included questions regarding pad use, soiling and need to alter activities owing to bowel function. The LARS score does not mention soiling but asks about accidental leakage of liquid stool. Accidental leakage was more common in the late closure group, although the difference between groups did not reach statistical significance. Urgency is one of the most debilitating components of postoperative bowel dysfunction according to patients, but is frequently underestimated by clinicians[31](#bjs11092-bib-0031){ref-type="ref"}, [37](#bjs11092-bib-0037){ref-type="ref"}. The urgency/soiling subscale is a misnomer as it does not include any questions about urgency, but question 11 in the MSKCC BFI asks about the ability to defer defecation. The median response in the early closure group was 'most of the time', whereas it was 'sometimes' possible for participants in the late closure group to be able to wait for 15 min to get to the toilet when they felt that they were going to have a bowel motion. Both the LARS score and the BFI questions regarding urgency showed that a greater proportion of people experience urgency after late closure, but neither difference between the treatment groups achieved statistical significance.

The secondary aim of this study was to provide a direct comparison of patient reporting using the LARS score and MSKCC BFI. These results showed a strong correlation between the two patient‐reported outcome scales, confirming that they are measuring the same underlying construct. The brevity of the LARS score and the greater dispersion of LARS scores suggest that the latter tool may be more appropriate than the BFI for a brief clinical assessment to identify patients who require further follow‐up for postoperative bowel dysfunction. The comprehensive BFI may be more suitable for longitudinal assessment of functional outcome as it has greater sensitivity to detect differences in symptomatology, as shown by the results on the urgency/soiling subscale here.

The strengths of this study are its randomized design and the high response rate. The major weakness is that it is a secondary analysis. The sample size for the EASY trial was calculated to achieve 80 per cent power to detect a reduction in mean annual complications[17](#bjs11092-bib-0017){ref-type="ref"}, and not a difference in functional outcome. In addition, the exclusion of participants who may have the most severe bowel dysfunction (those who opted for a permanent stoma) has probably led to an underestimation of major LARS in the late closure group. The higher proportion of women in the early closure group may have also led to an underestimation of the difference in rates of LARS between the treatment groups, as women have higher rates of LARS both after rectal resection and within the Danish population in other studies[20](#bjs11092-bib-0020){ref-type="ref"}, [38](#bjs11092-bib-0038){ref-type="ref"}. Another limitation is the cross‐sectional assessment of LARS. A longitudinal assessment would have been preferable. However, the minimum follow‐up for all participants was 24 months after restoration of bowel continuity and by this stage functional outcomes would be expected to be relatively stable.

LARS represents a significant burden for both rectal cancer survivors and the healthcare system. This study found that the prevalence of major LARS was up to 73 per cent for patients who had an ileosomy, if closed at the conventional time. The results indicate that specifically powered prospective randomized studies are required to assess definitively whether early closure of an ileostomy mitigates the development of LARS. It is anticipated that the present results will be informative in appropriate trial design.

Snapshot quiz 19/8 {#bjs11092-sec-8125}
==================

Supporting information
======================

###### 

**Appendix S1.** LARS Score (31)

**Appendix S2.** Memorial Sloan Kettering Cancer Center Bowel Function Instrument, adapted from (32)

###### 

Click here for additional data file.
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